Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$10.73B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  UTHR
United Therapeutics
UTHR
92 / 100
High Quality
High Growth
$237.92arrow_drop_up0.42%$1.00

Performance History

Stocklytics logo
Key Stats
Open$233.61
Prev. Close$234.47
EPS19.82
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$11.01B
PE Ratio11.96
LOWHIGH
Day Range233.61
241.00
52 Week Range204.44
261.54
Ratios
P/B Ratio1.83
Revenue$2.32B
Operating M. %42.49%
Earnings$984.80M
Earnings Growth %35.40%
EBITDA Margin %53.24%
ROE %18.27%
EPS19.82

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

92vs 54. Market Avg.

All Score 92 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

UTHRMARKET
Value4240
Quality9640
Ownership4217
Growth7745
Dividends-38
warning

United Therapeutics's Price growth average in the last 3 years of 4.73% is modest compared to market average of 5.46%. This indicates UTHR could be a bad value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$731.65
24H (%)arrow_drop_down1.88%
24H ($)-$14.03
MARKET CAP$695.32B
PRICE$487.37
24H (%)arrow_drop_up0.24%
24H ($)$1.19
MARKET CAP$452.88B
PRICE$148.53
24H (%)arrow_drop_down0.68%
24H ($)-$1.03
MARKET CAP$359.34B
PRICE$127.00
24H (%)arrow_drop_up0.09%
24H ($)$0.12
MARKET CAP$321.39B

About United Therapeutics (UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Headquarters
Silver Spring
Employees
985
Exchange
NASDAQ
add United Therapeutics to watchlist

Keep an eye on United Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the market capitalization of United Therapeutics (UTHR)?

United Therapeutics (UTHR) has a market capitalization of $11.01B. The average daily trading volume is 527.71K, indicating the stock's liquidity and investor engagement.

help
What is United Therapeutics's (UTHR) price per share?

The current price per share for United Therapeutics (UTHR) is $236.98. The stock has seen a price change of $2.51 recently, indicating a 1.07% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for United Therapeutics (UTHR)?

For United Therapeutics (UTHR), the 52-week high is $261.54, which is 10.36% from the current price. The 52-week low is $204.44, the current price is 15.92% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is United Therapeutics (UTHR) a growth stock?

United Therapeutics (UTHR) has shown an average price growth of 4.92% over the past three years. It has received a score of 64 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying United Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is United Therapeutics (UTHR) stock price performance year to date (YTD)?

As of the latest data, United Therapeutics (UTHR) has a year-to-date price change of 4.24%. Over the past month, the stock has experienced a price change of -2.98%. Over the last three months, the change has been 8.3%. Over the past six months, the figure is 4.29%. Looking at a longer horizon, the five-year price change stands at 128.97%.

help
Is United Therapeutics (UTHR) a profitable company?

United Therapeutics (UTHR) has a net income of $984.8M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 42.49% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.33B, with a revenue growth rate of 20.2%, providing insight into the company's sales performance and growth. The gross profit is $2.07B. Operating income is noted at $1.18B. Furthermore, the EBITDA is $1.39B.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.